Analyst Reco. Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Market Closed - Nasdaq Other stock markets 21:30:00 03/05/2024 BST			5-day change	1st Jan Change
1.36 ^USD	+3.82%		+13.33%	+29.52%

03-19	Aclaris Therapeutics, Inc. Announces Board Resignations	CI
02-27	Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Downgrades Aclaris Therapeutics to Neutral From Buy	01-22	MT
BTIG Downgrades Aclaris Therapeutics to Neutral From Buy	01-11	MT
Stifel Trims Price Target on Aclaris Therapeutics to $1 From $2, Maintains Hold Rating	12-18	MT
HC Wainwright Cuts Price Target on Aclaris Therapeutics to $9 From $43, Maintains Buy Rating	11-14	MT
Cantor Fitzgerald Downgrades Aclaris Therapeutics to Neutral From Overweight	11-14	MT
Evercore ISI Cuts Aclaris Therapeutics' Price Target to $3 From $22, Keeps Outperform Rating	11-13	MT
Piper Sandler Downgrades Aclaris Therapeutics to Neutral From Overweight, Cuts Price Target to $2 From $30	11-13	MT
Stifel Downgrades Aclaris Therapeutics to Hold From Buy, Cuts Price Target to $2 From $20	11-13	MT
William Blair Downgrades Aclaris Therapeutics to Market Perform From Outperform	11-13	MT
Evercore ISI Initiates Aclaris Therapeutics at Outperform Rating With $22 Price Target	03/10/23	MT
Stifel Adjusts Price Target on Aclaris Therapeutics to $20 From $16, Maintains Buy Rating	14/09/23	MT
Goldman Sachs Adjusts Price Target on Aclaris Therapeutics to $21 From $25, Maintains Buy Rating	07/03/23	MT
HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $43 From $50, Maintains Buy Rating	07/03/23	MT
BTIG Research Adjusts Aclaris Therapeutics Price Target to $29 From $32, Maintains Buy Rating	07/03/23	MT
Stifel Nicolaus Initiates Coverage on Aclaris Therapeutics With Buy Rating, $29 Price Target	14/12/22	MT
Goldman Sachs Initiates Aclaris Therapeutics at Buy With $25 Price Target	01/12/22	MT
BTIG Starts Aclaris Therapeutics at Buy With $32 Price Target	06/10/22	MT
ACLARIS THERAPEUTICS : HC Wainwright Adjusts Price Target on Aclaris Therapeutics to $50 From $40, Reiterates Buy Rating	16/06/21	MT
ACLARIS THERAPEUTICS : Piper Sandler Starts Aclaris Therapeutics at Overweight With $30 Price Target	15/06/21	MT
ACLARIS THERAPEUTICS : HC Wainwright Initiates Aclaris Therapeutics at Buy Rating With $40 Price Target	21/04/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Analyst Reco.

Filters